Pfizer shares jumped 4% Wednesday after it released positive results from its closely watched early-stage human trial of a coronavirus vaccine.
The trial evaluated 45 people. Each participant received 10, 30 or 100 microgram doses of the vaccine or a placebo.
The company said one of its four coronavirus vaccine candidates produced neutralizing antibodies, which researchers believe is necessary to build immunity to the virus, in all participants who received two of the 10 or 30 microgram doses after 28 days, according to the preliminary data, which was posted in a paper released on MedRXiv. The company said the levels